What clinicaltrials.gov entries or manufacturer registries list planned or ongoing long‑term follow‑up for the Janssen COVID‑19 vaccine, and what are their reported timelines?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
The principal ClinicalTrials.gov records tied to Janssen’s Ad26.COV2.S COVID‑19 vaccine that explicitly appear in this reporting are the Phase 3 ENSEMBLE trial (ClinicalTrials.gov identifier NCT04505722) and at least one other registry entry (NCT05037266) surfaced by the ClinicalTrials.gov search interface [1] [2] [3]. Public documents from NIH, FDA and CDC confirm that ENSEMBLE reported a required median two‑month follow‑up for its primary endpoints and promised “forthcoming reports” with more comprehensive and longer‑term analyses — but the assembled snippets do not specify a concrete multi‑year follow‑up schedule in the provided sources [4] [1] [5].
1. The main long‑term follow‑up vehicle named in official reporting: ENSEMBLE (NCT04505722)
The ENSEMBLE Phase 3 trial is repeatedly cited in NIH and journal reporting as the pivotal study for Janssen’s single‑dose Ad26.COV2.S vaccine and is identified on ClinicalTrials.gov under identifier NCT04505722 [1] [6] [7]. Public summaries state that the trial exceeded case targets and that the pre‑specified median two‑month follow‑up used for primary efficacy endpoints was complete; NIH and Janssen indicated that more comprehensive ENSEMBLE data and further analyses would be released in subsequent reports, which implies ongoing data collection or extended analyses beyond the initial median two‑month window [4] [1].
2. Other ClinicalTrials.gov records and the search trail (NCT05037266 and CTG search results)
The ClinicalTrials.gov index includes additional records linked to Janssen’s COVID vaccine program; one specific study identifier surfaced in the search snippets is NCT05037266, and ClinicalTrials.gov’s search portal was used to aggregate Janssen and COVID‑19 vaccine records [2] [3]. The provided material does not include full registry pages for those identifiers, so while these records exist in the public registry, the supplied excerpts do not reveal their stated follow‑up durations or explicit long‑term timelines [2] [3].
3. Manufacturer and regulator registries referenced as sources of follow‑up plans
Regulatory and manufacturer documents point readers to ClinicalTrials.gov for trial details: the FDA EUA fact sheet and Janssen/Johnson & Johnson public pages advise consulting ClinicalTrials.gov for trials testing the Janssen vaccine, and the ENSEMBLE trial is highlighted across NIH and Janssen materials [8] [9] [1]. FDA advisory materials discuss trial submissions and sponsor proposals (including a sponsor‑proposed crossover design) but the supplied excerpt does not quote a definitive long‑term follow‑up duration; instead it documents the regulatory dossier and proposed designs that would typically encompass continued safety surveillance [5].
4. Timelines that are explicitly reported in the supplied sources
The clearest timeline detail in these sources is that the Phase 3 trial met its primary endpoints with a required median two‑month follow‑up for efficacy analysis; NIH and NEJM reporting explicitly cite that two‑month median follow‑up underpinning the primary results and that more detailed long‑term data would be released later [4] [6] [1]. Beyond that two‑month benchmark, the provided snippets state that “forthcoming reports” and continued analyses were expected but do not provide exact multi‑month or multi‑year follow‑up lengths in the excerpts given [1].
5. Context and caveats: supply, EUA status and implications for follow‑up data availability
Regulatory context affects how follow‑up is presented: CDC archives note that U.S. government stock of Janssen vaccine expired May 7, 2023, and broader policy shifts (including preferential guidance for mRNA vaccines) and the manufacturer’s production pauses were documented elsewhere; Wikipedia notes the EUA revocation in June 2023 at the manufacturer’s request [10] [11]. These facts do not nullify clinical trial follow‑up that was or is being collected, but they are relevant when searching for registry updates or new manufacturer post‑authorization study commitments because availability and manufacturer priorities influence post‑market study activity [10] [11].
6. What the records do not (yet) show in the provided reporting
The assembled sources point to ClinicalTrials.gov entries (notably NCT04505722 and NCT05037266) and to regulatory briefing documents, and they document the two‑month median follow‑up used for primary efficacy analyses and a promise of further reports [1] [4] [5]. However, the supplied snippets do not include complete ClinicalTrials.gov record text that would state explicit planned durations (for example, one‑year or two‑year safety follow‑up periods) for ongoing long‑term follow‑up; therefore it is not possible from these excerpts alone to list definitive multi‑year timelines or enrollment windows beyond what is cited above [2] [3].